Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study

被引:34
|
作者
Rostock, Matthias [1 ,2 ]
Fischer, Julia [2 ]
Mumm, Andreas [2 ]
Stammwitz, Ute [3 ]
Saller, Reinhard [1 ]
Bartsch, Hans Helge [2 ]
机构
[1] Univ Zurich Hosp, Inst Complementary Med, CH-8091 Zurich, Switzerland
[2] Univ Freiburg, Tumor Biol Ctr, Freiburg, Germany
[3] GmbH & Co KG, Schaper & Brummer, Salzgitter, Germany
关键词
Black cohosh; Cimicifuga racemosa; climacteric complaints; hot flushes; breast cancer; tamoxifen; Menopause Rating Scale II; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN; HOT FLASHES; MENOPAUSAL SYMPTOMS; EFFICACY; THERAPY; EXTRACT; PLACEBO; TRIAL; MANAGEMENT;
D O I
10.3109/09513590.2010.538097
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The antihormonal therapy of breast cancer patients with the antiestrogen tamoxifen often induces or aggravates menopausal complaints. As estrogen substitution is contraindicated, herbal alternatives, e. g. extracts of black cohosh are often used. Design. A prospective observational study was carried out in 50 breast cancer patients with tamoxifen treatment. All patients had had surgery, most of them had undergone radiation therapy (87%) and approximately 50% had received chemotherapy. Every patient was treated with an isopropanolic extract of black cohosh (1-4 tablets, 2.5 mg) for 6 months. Patients recorded their complaints before therapy and after 1, 3, and 6 months of therapy using the menopause rating scale (MRS II). Results. The reduction of the total MRS II score under black cohosh treatment from 17.6 to 13.6 was statistically significant. Hot flashes, sweating, sleep problems, and anxiety improved, whereas urogenital and musculoskeletal complaints did not change. In all, 22 patients reported adverse events, none of which were linked with the study medication; 90% reported the tolerability of the black cohosh extract as very good or good. Conclusions. Black cohosh extract seems to be a reasonable treatment approach in tamoxifen treated breast cancer patients with predominantly psychovegetative symptoms.
引用
收藏
页码:844 / 848
页数:5
相关论文
共 50 条
  • [42] The prognostic importance of various clinical, pathological, and immunohistochemical parameters in tamoxifen-treated patients with early breast cancer
    Mermershtain, W.
    Lazarev, I.
    Geffen, D. B.
    Grinberg, V.
    Ariad, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 305 - 306
  • [43] The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients
    Markovitch, O
    Tepper, R
    Fishman, A
    Shapira, J
    Aviram, R
    Cohen, I
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 456 - 462
  • [44] Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients
    Kirkegaard, Tove
    McGlynn, Liane M.
    Campbell, Fiona M.
    Mueller, Sven
    Tovey, Sian M.
    Dunne, Barbara
    Nielsen, Kirsten V.
    Cooke, Timothy G.
    Bartlett, John M. S.
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1405 - 1411
  • [45] Sequenced aromatase inhibitor use associated with lower risk of endometrial cancer in tamoxifen-treated breast cancer patients: a population-based study
    Chu, S-C.
    Hsieh, C-J.
    Wang, T-F.
    Hong, M-K.
    Chu, T-Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] The predictive value of Her2/neu status on clinical outcome in tamoxifen-treated breast cancer patients
    Hanna, W
    Wong, JW
    Zubovits, J
    Trudeau, M
    LABORATORY INVESTIGATION, 2003, 83 (01) : 32A - 32A
  • [47] DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients
    Maier, S
    Nimmrich, I
    Marx, A
    Eppenberger-Castori, S
    Jaenicke, F
    Paradiso, A
    Spyratos, F
    Foekens, J
    Schmitt, M
    Harbeck, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 9S - 9S
  • [48] The predictive value of Her2/neu status on clinical outcome in tamoxifen-treated breast cancer patients
    Hanna, W
    Wong, JW
    Zubovits, J
    Trudeau, M
    MODERN PATHOLOGY, 2003, 16 (01) : 32A - 32A
  • [49] Comparison of hysteroscopic and hysterectomy findings to assess the diagnostic accuracy of office hysteroscopy in tamoxifen-treated patients with breast cancer
    Ceci, O
    Bettocchi, S
    Nappi, L
    Di Venere, R
    Pansini, MV
    Di Fazio, F
    JOURNAL OF THE AMERICAN ASSOCIATION OF GYNECOLOGIC LAPAROSCOPISTS, 2003, 10 (03): : 392 - 395
  • [50] CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients
    Ramirez, Gabriel
    Vital, Marcelo
    Vergara, Carolina
    Carusso, Florencia
    Neffa, Florencia
    Valle, Adriana Della
    Esperon, Patricia
    PERSONALIZED MEDICINE, 2023, : 477 - 483